Skip to main navigation Skip to search Skip to main content

Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports

  • Gustavo Savino
  • , Remo Battendieri
  • , Andrea Siniscalco
  • , Erika Mandara'
  • , Antonino Mule'
  • , Gianluigi Petrone
  • , Salvatore Traina
  • , Monica Riso

Research output: Contribution to journalArticle

Abstract

We report a case of a 66-year-old Caucasian female with a diagnosis of idiopathic orbital inflammatory disease (OID) refractory to azathioprine therapy. The coexistence of diabetes mellitus represented a relative contraindication to chronic prednisone use. After two infusions of rituximab, a chimeric anti-CD20+ antibody, ophthalmic signs and symptoms remarkably improved. To our knowledge, this is the first case of idiopathic OID successfully treated with rituximab.
Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalRheumatology International
Volume35
DOIs
Publication statusPublished - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • idiopathic orbital inflammatory syndrome:

Fingerprint

Dive into the research topics of 'Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports'. Together they form a unique fingerprint.

Cite this